Treatment of Immunoglobulin Light Chain Amyloidosis
- 1 August 2015
- journal article
- review article
- Published by Elsevier BV in Mayo Clinic Proceedings
- Vol. 90 (8), 1054-1081
- https://doi.org/10.1016/j.mayocp.2015.06.009
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- Utility of Doppler Myocardial Imaging, Cardiac Biomarkers, and Clonal Immunoglobulin Genes to Assess Left Ventricular Performance and Stratify Risk Following Peripheral Blood Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis (AL)Journal of the American Society of Echocardiography, 2011
- Antibodies to human serum amyloid P component eliminate visceral amyloid depositsNature, 2010
- Kidney dysfunction during lenalidomide treatment for AL amyloidosisNephrology Dialysis Transplantation, 2010
- Discordance between serum cardiac biomarker and immunoglobulin‐free light‐chain response in patients with immunoglobulin light‐chain amyloidosis treated with immune modulatory drugsAmerican Journal of Hematology, 2010
- Structural Alterations within Native Amyloidogenic Immunoglobulin Light ChainsJournal of Molecular Biology, 2009
- Intracardiac Thrombosis and Anticoagulation Therapy in Cardiac AmyloidosisCirculation, 2009
- Diagnostic and Prognostic Utility of Cardiovascular Magnetic Resonance Imaging in Light-Chain Cardiac AmyloidosisThe American Journal of Cardiology, 2009
- Heterogeneity in Primary Structure, Post-Translational Modifications, and Germline Gene Usage of Nine Full-Length Amyloidogenic κ1 Immunoglobulin Light ChainsBiochemistry, 2007
- Localized amyloidosis: A survey of 35 French casesAmyloid, 2005
- Digoxin sensitivity in amyloid cardiomyopathy.Circulation, 1981